Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2016 3
2017 4
2019 3
2020 4
2021 11
2022 3
2023 5
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

30 results

Results by year

Filters applied: . Clear all
Page 1
Effects of baricitinib, empagliflozin, linagliptin and telmisartan on cardiovascular autonomic neuropathy in type 1 diabetes: An exploratory, randomized, open-label, crossover trial.
Laursen JC, Rotbain Curovic V, Kroonen MYAM, Jongs N, Zobel EH, Hansen TW, Frimodt-Møller M, Laverman GD, Kooy A, Persson F, Heerspink HJL, Hansen CS, Rossing P. Laursen JC, et al. Among authors: zobel eh. Diabetes Obes Metab. 2023 Oct;25(10):3064-3067. doi: 10.1111/dom.15180. Epub 2023 Jun 29. Diabetes Obes Metab. 2023. PMID: 37385968 Clinical Trial. No abstract available.
Increased Subclinical Coronary Artery Pathology in Type 2 Diabetes With Albuminuria.
Bull Rasmussen IK, Skriver-Moeller AC, Ripa RS, Hasbak P, Wasehuus VS, Hadji-Turdeghal K, Zobel EH, Lassen ML, Holmvang L, Slomka P, Rossing P, Kjaer A, Hansen TW. Bull Rasmussen IK, et al. Among authors: zobel eh. Diabetes. 2024 Mar 1;73(3):490-496. doi: 10.2337/db23-0529. Diabetes. 2024. PMID: 37992197
Overall and inter-individual effect of four different drug classes on soluble urokinase plasminogen activator receptor in type 1 and type 2 diabetes.
Rotbain Curovic V, Houlind MB, Kroonen MYAM, Jongs N, Zobel EH, Hansen TW, Tavenier J, Eugen-Olsen J, Laverman GD, Kooy A, Persson F, Rossing P, Heerspink HJL. Rotbain Curovic V, et al. Among authors: zobel eh. Diabetes Obes Metab. 2023 Nov;25(11):3152-3160. doi: 10.1111/dom.15209. Epub 2023 Jul 7. Diabetes Obes Metab. 2023. PMID: 37417375 Clinical Trial.
Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY): a prospective observational study and embedded randomised placebo-controlled trial.
Tofte N, Lindhardt M, Adamova K, Bakker SJL, Beige J, Beulens JWJ, Birkenfeld AL, Currie G, Delles C, Dimos I, Francová L, Frimodt-Møller M, Girman P, Göke R, Havrdova T, Heerspink HJL, Kooy A, Laverman GD, Mischak H, Navis G, Nijpels G, Noutsou M, Ortiz A, Parvanova A, Persson F, Petrie JR, Ruggenenti PL, Rutters F, Rychlík I, Siwy J, Spasovski G, Speeckaert M, Trillini M, Zürbig P, von der Leyen H, Rossing P; PRIORITY investigators. Tofte N, et al. Lancet Diabetes Endocrinol. 2020 Apr;8(4):301-312. doi: 10.1016/S2213-8587(20)30026-7. Epub 2020 Mar 2. Lancet Diabetes Endocrinol. 2020. PMID: 32135136 Clinical Trial.
Ceramides are decreased after liraglutide treatment in people with type 2 diabetes: a post hoc analysis of two randomized clinical trials.
Wretlind A, Curovic VR, de Zawadzki A, Suvitaival T, Xu J, Zobel EH, von Scholten BJ, Ripa RS, Kjaer A, Hansen TW, Vilsbøll T, Vestergaard H, Rossing P, Legido-Quigley C. Wretlind A, et al. Among authors: zobel eh. Lipids Health Dis. 2023 Sep 26;22(1):160. doi: 10.1186/s12944-023-01922-z. Lipids Health Dis. 2023. PMID: 37752566 Free PMC article.
30 results